Novo's €2.6bn Ablynx Bid Opens The Door For Better Offers
Gilead, Amgen and AbbVie are names that could join the fray should a bidding war start for Nanobody drug developer Ablynx, which has rebuffed two takeover offers from Novo Nordisk.
You may also be interested in...
Sanofi's €3.9bn acquisition of Ablynx will allow the French big pharma to build up its rare blood disorder pipeline and bring in complementary programs in areas like respiratory infections.
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.
As participants from this year’s J.P. Morgan Healthcare conference recover from the torrent of new information they were exposed to, Scrip explores which biotechs saw a sustainable shift in their valuations.